{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:05:56Z","timestamp":1786989956729,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.gtc.2014.05.011","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T23:45:17Z","timestamp":1403567117000},"page":"603-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Update on Janus Kinase Antagonists in Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Brigid S.","family":"Boland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2014.05.011_bib1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib2","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.011_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.gtc.2014.05.011_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.gtc.2014.05.011_bib5","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.gtc.2014.05.011_bib6","first-page":"1347","article-title":"JAK2, a third member of the JAK family of protein tyrosine kinases","volume":"7","author":"Harpur","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.gtc.2014.05.011_bib7","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.gtc.2014.05.011_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.gtc.2014.05.011_bib9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.gtc.2014.05.011_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.gtc.2014.05.011_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","article-title":"Signaling by type I and II cytokine receptors: ten years after","volume":"13","author":"Gadina","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.gtc.2014.05.011_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1042\/bj20021935","article-title":"Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3","volume":"370","author":"Dumoutier","year":"2003","journal-title":"Biochem J"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2014.05.011_bib13","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2014.05.011_bib14","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gtc.2014.05.011_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.gtc.2014.05.011_bib16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jpeds.2012.01.056","article-title":"A\u00a0patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome","volume":"160","author":"Kilic","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.gtc.2014.05.011_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/1521-4141(200003)30:3<732::AID-IMMU732>3.0.CO;2-L","article-title":"Intrinsic defects of B cell function in X-linked severe combined immunodeficiency","volume":"30","author":"White","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.gtc.2014.05.011_bib19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2010.02.012","article-title":"B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review","volume":"125","author":"Buckley","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.gtc.2014.05.011_bib20","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.011_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.immuni.2008.04.016","article-title":"Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation","volume":"28","author":"Shi","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.gtc.2014.05.011_bib22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMra1100030","article-title":"Genomics and the multifactorial nature of human autoimmune disease","volume":"365","author":"Cho","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.gtc.2014.05.011_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A\u00a0quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.gtc.2014.05.011_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J\u00a0Inflamm (Lond)"},{"key":"10.1016\/j.gtc.2014.05.011_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.gtc.2014.05.011_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A\u00a0phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2014.05.011_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.011_bib35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.011_bib36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/apt.12262","article-title":"The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome","volume":"37","author":"Lahiff","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2014.05.011_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2014.05.011_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2014.05.011_bib39","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-013-2329-9","article-title":"The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"32","author":"Kawalec","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gtc.2014.05.011_bib40","unstructured":"Pfizer. Advisory Committee Meeting: Tofacitinib for treatment of rheumatoid arthritis (NDA 203214). May 9, 2012 edition. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM302960\/. Accessed February 14, 2014."},{"key":"10.1016\/j.gtc.2014.05.011_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2014.05.011_bib42","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2014.05.011_bib43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.011_bib44","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.gtc.2014.05.011_bib45","first-page":"S431","article-title":"A\u00a0randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK 1&2) inhibitor in rheumatoid arthritis (RA)","volume":"58","author":"Williams","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2014.05.011_bib46","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1136\/annrheumdis-2012-eular.1965","article-title":"12-Week results of a Phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAJ\/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2014.05.011_bib47","unstructured":"Janssen Research & Development, LLC. A study of safety and effectiveness of JNJ-54781532 in patients with moderately to severely active ulcerative colitis. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (USA); 2000-2014. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01959282."},{"key":"10.1016\/j.gtc.2014.05.011_bib48","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1136\/annrheumdis-2012-eular.1946","article-title":"Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis: results of a phase IIa trial","volume":"71","author":"Vanhoutte","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2014.05.011_bib49","doi-asserted-by":"crossref","unstructured":"Merciris D, Delachaume C, De Vriendt V, et\u00a0al. GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model. Congress of ECCO. Denmark, February 21, 2014.","DOI":"10.1016\/S1873-9946(14)60194-X"},{"key":"10.1016\/j.gtc.2014.05.011_bib50","first-page":"LB3","article-title":"Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA)","volume":"63","author":"Fleischmann","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2014.05.011_bib51","doi-asserted-by":"crossref","unstructured":"Vanhoutte F, Namour F, Dupont S, et\u00a0al. The FFA2 antagonist GLPG0974: opportunity to treat neutrophil-driven inflammation. Congress of ECCO. 2014.","DOI":"10.1016\/S1873-9946(14)60095-7"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855314000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855314000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:24Z","timestamp":1760178444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855314000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0889855314000685"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2014.05.011","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Janus Kinase Antagonists in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2014.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}